Table 3 Frequency of adverse events reported in dogs randomized to receive either fluralaner flavored chewable tablets or spinosad together with amitraz
Adverse Event | Fluralaner, dogs observed over 26 weeks | Spinosad + Amitraz, dogs observed over 12 weeks |
|---|---|---|
(N = 224) | (N = 70) | |
Emesis | 16 (7.1%) | 10 (14.3%) |
Decreased appetite | 15 (6.7%) | 0 (0.0%) |
Diarrhea | 11 (4.9%) | 2 (2.9%) |
Lethargy | 12 (5.4%) | 5 (7.1%) |
Polydipsia | 4 (1.8%) | 3 (4.3%) |
Flatulence | 3 (1.3%) | 0 (0.0%) |